SCHEMBL10114749

SCHEMBL10114749

CC(C)S(=O)(=O)NC1CCC(C(=O)Nc2ccc(N3C[C@H](C)C[C@@H](C)C3)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.41
EPHX2 P34913 2/20 0.41
NAMPT P43490 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MCHR1 Q99705 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ROCK2 O75116 2/20 0.39
RPS6KA5 O75582 2/20 0.39
ROCK1 Q13464 2/20 0.39
PKN2 Q16513 2/20 0.39
LRRK2 Q5S007 2/20 0.39
CHUK O15111 1/20 0.39
PRKD3 O94806 1/20 0.39
CDK1 P06493 1/20 0.39
CDK2 P24941 1/20 0.39
LTK P29376 1/20 0.39
CDK8 P49336 1/20 0.39
PRKX P51817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10114744 1.00 MEN1 (0.42) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL14424789 1.00 MEN1 (0.42) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL10134423 1.00 MEN1 (0.42) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL13204310 1.00 MEN1 (0.42) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL10134424 1.00 MEN1 (0.42) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL13204312 1.00 MEN1 (0.42) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL10113964 0.88 MAPT (0.49) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL10114302 0.88 MAPT (0.49) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL13204286 0.88 MAPT (0.49) MEN1KMT2AALDH1A1EPHX2NAMPT
SCHEMBL10114125 0.88 MAPT (0.49) MEN1KMT2AALDH1A1EPHX2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2932/4885KMT2A 2768/4885ALDH1A1 4599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.